

Mauritania

Population 2016

4.3 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.89 (0.53–1.4)	21 (12–31)
Mortality (HIV+TB only)	0.09 (0.034–0.17)	2.1 (0.8–4)
Incidence (includes HIV+TB)	4.4 (2.8–6.3)	102 (66–146)
Incidence (HIV+TB only)	0.22 (0.084–0.42)	5.1 (2–9.8)
Incidence (MDR/RR-TB)**	0.14 (0.023–0.26)	3.3 (0.53–6)

Estimated TB incidence by age and sex (thousands)*, 2016			
	0-14 years	> 14 years	Total
Females	0.26 (0.16–0.36)	1.4 (0.86–2)	1.7 (1–2.3)
Males	0.29 (0.18–0.41)	2.4 (1.5–3.4)	2.7 (1.7–3.8)
Total	0.55 (0.33–0.76)	3.8 (2.3–5.3)	4.4 (2.8–6.3)

TB case notifications, 2016	
Total cases notified	2 386
Total new and relapse	2 359
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	0%
- % pulmonary	70%
- % bacteriologically confirmed among pulmonary	79%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2016	54% (38–83)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.23 (0.12–0.38)

TB/HIV care in new and relapse TB patients, 2016		Number	(%)
Patients with known HIV-status who are HIV-positive			
- on antiretroviral therapy			

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			60 (15–100)
Estimated % of TB cases with MDR/RR-TB	2.6% (0.1–5.1)	18% (0.1–36)	
% notified tested for rifampicin resistance	0%	7%	8
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 8, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 8, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	71%	2 166
Previously treated cases, excluding relapse, registered in 2015	59%	27
HIV-positive TB cases registered in 2015		0
MDR/RR-TB cases started on second-line treatment in 2014	0%	14
XDR-TB cases started on second-line treatment in 2014		0

TB preventive treatment, 2016	
% of HIV-positive people (newly enrolled in care) on preventive treatment	0%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2017	
National TB budget (US\$ millions)	<1
Funding source: 32% domestic, 68% international, 0% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)



— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016




Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



■ Unfunded
■ Funded internationally
■ Funded domestically